Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yim, Hyung Joon | - |
dc.contributor.author | Suh, Sang Jun | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Hwang, Seong Gyu | - |
dc.contributor.author | Seo, Yeon Seok | - |
dc.contributor.author | Um, Soon Ho | - |
dc.contributor.author | Lee, Sae Hwan | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Jang, Jae Young | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Kim, Hyoung Su | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Lee, Young Sun | - |
dc.contributor.author | Yoon, Eileen L. | - |
dc.contributor.author | Song, Myeong Jun | - |
dc.contributor.author | Park, Jun Yong | - |
dc.date.accessioned | 2021-08-30T06:38:07Z | - |
dc.date.available | 2021-08-30T06:38:07Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-12 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/51236 | - |
dc.description.abstract | The treatment of multidrug-resistant (MDR) chronic hepatitis B (CHB) is challenging. Herein, we report a multicenter prospective cohort study for the evaluation of tenofovir disoproxil fumarate (TDF)-based therapy for MDR CHB in a real-life setting. The inclusion criteria comprised patients with resistance to more than two nucleos(t)ide analogue (NA) classes and hepatitis B virus (HBV) DNA level of >= 200 IU/mL. The primary end-point was virologic response (VR), defined as undetectable HBV DNA (<20 IU/mL) after 60 months. A total of 236 patients met the inclusion criteria. The mean HBV DNA level was 4.16 +/- 1.44 log IU/mL; 26.7% of patients had liver cirrhosis. Before the initiation of TDF, 33.5%, 44.9% and 21.6% of patients had mutations resistant to L-NA + adefovir, L-NA + entecavir (ETV) and L-NA + adefovir + ETV, respectively. A total of 184 patients received TDF-based combination therapy [TDF + ETV (n = 178) or TDF + L-NA (n = 6)], and 52 patients received TDF monotherapy. In the entire cohort, the VR rates were 77.2%, 89.9% and 92.2% at 12, 36 and 60 months, respectively. The VR rates were not significantly different between the combination therapy and the monotherapy group after 12 (76.2% vs 80.4%,P = .533), 36 (89.8% vs 90.3%,P = 1.000) or 60 (92.9% vs 87.5%,P = .499) months. Also, there was no significant difference in the cumulative VR rates for 5 years between the treatment groups (P = .910). Newly developed antiviral resistance was not observed. TDF-based therapy was effective for the treatment of MDR CHB. The efficacy of TDF monotherapy was not different from that of the TDF-based combination therapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | DISOPROXIL FUMARATE | - |
dc.subject | ADEFOVIR DIPIVOXIL | - |
dc.subject | RESCUE THERAPY | - |
dc.subject | VIRUS INFECTION | - |
dc.subject | NAIVE PATIENTS | - |
dc.subject | ENTECAVIR | - |
dc.subject | LAMIVUDINE | - |
dc.subject | EFFICACY | - |
dc.subject | FAILURE | - |
dc.title | Tenofovir-based combination therapy or monotherapy for multidrug-resistant chronic hepatitis B: Long-term data from a multicenter cohort study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Young Kul | - |
dc.contributor.affiliatedAuthor | Kim, Ji Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Young Sun | - |
dc.identifier.doi | 10.1111/jvh.13363 | - |
dc.identifier.scopusid | 2-s2.0-85089586274 | - |
dc.identifier.wosid | 000560940900001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, v.27, no.12, pp.1306 - 1318 | - |
dc.relation.isPartOf | JOURNAL OF VIRAL HEPATITIS | - |
dc.citation.title | JOURNAL OF VIRAL HEPATITIS | - |
dc.citation.volume | 27 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1306 | - |
dc.citation.endPage | 1318 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | DISOPROXIL FUMARATE | - |
dc.subject.keywordPlus | ADEFOVIR DIPIVOXIL | - |
dc.subject.keywordPlus | RESCUE THERAPY | - |
dc.subject.keywordPlus | VIRUS INFECTION | - |
dc.subject.keywordPlus | NAIVE PATIENTS | - |
dc.subject.keywordPlus | ENTECAVIR | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | FAILURE | - |
dc.subject.keywordAuthor | chronic hepatitis B | - |
dc.subject.keywordAuthor | multidrug resistance | - |
dc.subject.keywordAuthor | tenofovir | - |
dc.subject.keywordAuthor | therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.